Xilio Therapeutics, Inc.XLONASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank33
3Y CAGR-12.4%
5Y CAGR+2.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-12.4%/yr
Annual compound
5Y CAGR
+2.3%/yr
Recent deceleration
Percentile
P33
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $59.91M | -10.5% |
| 2024 | $66.93M | -15.4% |
| 2023 | $79.13M | -11.2% |
| 2022 | $89.15M | +21.2% |
| 2021 | $73.55M | +37.5% |
| 2020 | $53.50M | +184.8% |
| 2019 | $18.79M | - |